Nyxoah Rings the Closing Bell at Nasdaq while Preparing for U.S. Market Launch of Innovative Sleep Apnea Device

Nyxoah SA recently celebrated its progress by ringing the Closing Bell at Nasdaq. This Belgian medical technology company specializes in innovative solutions for Obstructive Sleep Apnea (OSA), a severe sleep-related disorder.

The company has completed its FDA submission for the Genio® device and expects U.S. approval by the end of 2024. Nyxoah plans to launch the device in the U.S. at the beginning of 2025, supported by more than €85 million in newly raised capital.

Olivier Taelman, CEO, emphasized the strategic importance of the U.S. market, highlighting the company’s strengthened commercial team. The Genio® device, which is designed to treat OSA via hypoglossal nerve stimulation, has shown positive results in the DREAM study.

Nyxoah's commercialization strategy includes building a robust U.S. organization and securing FDA approval. The company’s successful fundraising efforts ensure the project is fully financed.